Life With Migraine: Effects on Relationships, Career, and Finances From the Chronic Migraine Epidemiology and Outcomes (CaMEO) Study

Buse, Dawn C.; Fanning, Kristina M.; Reed, Michael L.; Murray, Sharron; Dumas, Paula K.; Adams, Aubrey Manack; Lipton, Richard B.

doi:10.1111/head.13613

Cited by 189 publications

(227 citation statements)

References 38 publications

Supporting

Mentioning

211

Contrasting

Unclassified

Order By: Relevance

“…A typical migraine presents with a recurrent, unilateral and episodic headache of moderate to severe intensity [7]. Both endometriosis and migraine portend substantial morbidity with wide-ranging socioeconomic burdens to sufferers, their families, relationships, and the society at large [8][9][10][11]. Notably, the diagnosis of the two disorders is challenging, due to a lack of diagnostic markers, which often results in missed or delayed diagnosis.…”

Section: Introductionmentioning

confidence: 99%

Shared Molecular Genetic Mechanisms Underlie Endometriosis and Migraine Comorbidity

Adewuyi

Sapkota

Auta

et al. 2020

Genes

View full text Add to dashboard Cite

Observational epidemiological studies indicate that endometriosis and migraine co-occur within individuals more than expected by chance. However, the aetiology and biological mechanisms underlying their comorbidity remain unknown. Here we examined the relationship between endometriosis and migraine using genome-wide association study (GWAS) data. Single nucleotide polymorphism (SNP) effect concordance analysis found a significant concordance of SNP risk effects across endometriosis and migraine GWAS. Linkage disequilibrium score regression analysis found a positive and highly significant genetic correlation (rG = 0.38, P = 2.30 × 10−25) between endometriosis and migraine. A meta-analysis of endometriosis and migraine GWAS data did not reveal novel genome-wide significant SNPs, and Mendelian randomisation analysis found no evidence for a causal relationship between the two traits. However, gene-based analyses identified two novel loci for migraine. Also, we found significant enrichment of genes nominally associated (Pgene < 0.05) with both traits (Pbinomial-test = 9.83 × 10−6). Combining gene-based p-values across endometriosis and migraine, three genes, two (TRIM32 and SLC35G6) of which are at novel loci, were genome-wide significant. Genes having Pgene < 0.1 for both endometriosis and migraine (Pbinomial-test = 1.85 ×10−°3) were significantly enriched for biological pathways, including interleukin-1 receptor binding, focal adhesion-PI3K-Akt-mTOR-signaling, MAPK and TNF-α signalling. Our findings further confirm the comorbidity of endometriosis and migraine and indicate a non-causal relationship between the two traits, with shared genetically-controlled biological mechanisms underlying the co-occurrence of the two disorders.

show abstract

Section: Introductionmentioning

confidence: 99%

Shared Molecular Genetic Mechanisms Underlie Endometriosis and Migraine Comorbidity

Adewuyi

Sapkota

Auta

et al. 2020

Genes

View full text Add to dashboard Cite

show abstract

“…1 The incapacitating nature of migraine can lead to marked individual disability and can exert a substantial impact on many aspects of life, including social and emotional well-being, family, career, and finances. 2 - 6 For these reasons, migraine was identified as one of the leading causes of years lived with disability in the 2017 Global Burden of Diseases, Injuries, and Risk Factors Study. 7…”

Section: Introductionmentioning

confidence: 99%

Migraine Patients With Cardiovascular Disease and Contraindications: An Analysis of Real-World Claims Data

Dodick

Shewale

Lipton

et al. 2020

J Prim Care Community Health

Self Cite

View full text Add to dashboard Cite

Introduction: Triptans, the most commonly prescribed acute treatments for migraine attacks are, per FDA labeling, contraindicated in cardiovascular (CV) disease patients and have warnings and precautions for those with CV risk factors. Methods: Headache specialists, cardiologists, and health economics and outcomes researchers convened to identify diagnostic codes for: (1) CV diseases contraindicating triptans based on FDA labeling; (2) conditions comprising “other significant underlying CV disease”; and (3) CV risk factors included as warnings and precautions for triptans. A retrospective, cross-sectional analysis of commercially insured adult US migraine patients in the 2017 Optum® Clinformatics® Data Mart (CDM) and the 2017 IBM® Watson Health MarketScan® Commercial Claims database was used to estimate the proportion of migraine patients with CV contraindications and warnings and precautions to triptans. Results: Of the 56,662 migraine patients analyzed from Optum CDM, 13.5% had ≥1 CV disease as specified in triptan labeling and an additional 8.5% had ≥1 “other CV disease” judged by the panel to constitute a “significant underlying CV disease” (total: 22.0% migraine patients). Of 176 724 migraine patients analyzed from MarketScan, 12.2% had ≥1 CV disease as specified in the labeling and an additional 8.0% had ≥1 “other significant underlying CV disease” (total: 20.2% of migraine patients). An additional 25.4% and 25.1% of migraine patients had ≥2 CV risk factors in Optum CDM and MarketScan. In total, 47.4% and 45.3% of migraine patients in both databases had a CV disease specified as a contraindication, an “other CV disease” endorsed as significant, or ≥2 CV risk factors identified as warnings and precautions to triptans. Conclusions: Analyses of more than 230,000 people with migraine showed that ≥20% of commercially insured US migraine patients have a CV condition that specifically contraindicates triptan treatment, and an additional 25% have ≥2 CV risk factors identified as warnings and precautions to triptans.

show abstract

“…Chronic migraine is a very common neurological disease worldwide, and the global prevalence is typically range from 1.4-2.2% [1]. Chronic migraine has great negative effects on the quality of life, psychological health, interpersonal relationships, and nancial stability of family [2]. Studies suggest that chronic migraine usually develops from episodic migraine that gradually increases in attack frequency, with an annual progression rate of about 3% [3].…”

Section: Introductionmentioning

confidence: 99%

Botulinum Neurotoxin A Prevents the Development of Nitroglycerin-Induced Chronic Migraine via Inhibition of CGRP and NLRP3 Inflammasomes in Mice

Tao

Niu

et al. 2020

Preprint

View full text Add to dashboard Cite

Background This study was designed to examine the therapeutic effects of Botulinum neurotoxin A (BoNT/A) on chronic migraine and to explore the potential mechanisms by using a mouse model of chronic migraine, which was established by repeated intraperitoneal (i.p.) injection with nitroglycerin (NTG).Methods NTG-induced basal and evoked mechanical hypersensitivity were evaluated using the von Frey filament test. Before the first injection of NTG, a single facial injection of BoNT/A was administered in the supraorbital region to explore its preventive effects on the development of chronic migraine in mice. The expression of calcitonin gene-related peptide (CGRP) and synaptosomal-associated protein25 (SNAP25) in the trigeminal ganglia (TG) and the trigeminal nucleus caudalis (TNC) were detected by Western blotting and immunostaining. Results Repeated administration of NTG resulted in basal and evoked mechanical hypersensitivity in mice. Single facial BoNT/A injection prevented the development of NTG-induced mechanical hypersensitivity in mice. Western blotting results revealed that peripheral BoNT/A injection decreased the NTG-induced upregulation of expression of CGRP and SNAP25 in the TGs and NOD-, LRR- and pyrin domain-containing protein 3 (NLRP3) inflammasomes in the TNC. Immunostaining results revealed peripheral BoNT/A injection also decreased the NTG-induced upregulation of CGRP expression in the TNC.Conclusions Thus, these results indicate that single facial injection of BoNT/A may be a preventive treatment of chronic migraine, possible due to the inhibitory effect of BoNT/A on the expression of CGRP and SNAP25 in the TGs and NLRP3 inflammasomes in the TNC.

show abstract

Life With Migraine: Effects on Relationships, Career, and Finances From the Chronic Migraine Epidemiology and Outcomes (CaMEO) Study

Cited by 189 publications

References 38 publications

Shared Molecular Genetic Mechanisms Underlie Endometriosis and Migraine Comorbidity

Shared Molecular Genetic Mechanisms Underlie Endometriosis and Migraine Comorbidity

Migraine Patients With Cardiovascular Disease and Contraindications: An Analysis of Real-World Claims Data

Botulinum Neurotoxin A Prevents the Development of Nitroglycerin-Induced Chronic Migraine via Inhibition of CGRP and NLRP3 Inflammasomes in Mice

Contact Info

Product

Resources

About